Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.42 |
| ▸ | HTR2C | P28335 | 17/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487269 | 0.88 | HTR2A (0.53) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL8319596 | 0.82 | HTR2A (0.44) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL12439352 | 0.82 | HTR2A (0.44) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL799374 | 0.82 | HTR2A (0.44) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL16529768 | 0.77 | L3MBTL3 (0.37) | HTR2AHTR2CL3MBTL1 | |
| SCHEMBL21722868 | 0.75 | HTR2A (0.31) | HTR2AHTR2C | |
| SCHEMBL195898 | 0.74 | — | — | |
| SCHEMBL7031908 | 0.73 | HTR2A (0.63) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14384741 | 0.73 | — | — | |
| SCHEMBL13178388 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| CN-112888675-A | Novel sulfonylurea compound | 英夫拉索姆有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112672995-A | Novel sulfonamide urea compounds | 英夫拉索姆有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| WO-2020035464-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035466-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | NLRP3, NOD1, NLRP1 | HTR2A 2089/4885HTR2C 2541/4885L3MBTL1 2098/4885 |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | HTR2A 1403/4885HTR2C 1742/4885L3MBTL1 2483/4885 |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | HTR2A 1380/4885HTR2C 1644/4885L3MBTL1 2185/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | HTR2A 1022/4885HTR2C 1083/4885L3MBTL1 2645/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | HTR2A 1380/4885HTR2C 1644/4885L3MBTL1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.